Showing 3021-3030 of 4166 results for "".
- Aldeyra Therapeutics Announces Positive Topline Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-data-from-phase-2-dry-eye-chamber-clinical-trial-of-reproxalap-for-dry-eye-disease/2480557/Aldeyra Therapeutics announced positive topline data from a phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra (lifitegrast ophthalmic solution 5%) in patients with dry ey
- Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-12a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2480529/Clearside Biomedical announced positive safety results from OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector. OASIS is evaluating CLS-AX for the treatment o
- Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Diabetic Retinal Disease to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meetinghttps://modernod.com/news/ocuphires-clinical-phase-2b-oral-drug-candidate-apx3330-for-diabetic-retinal-disease-to-be-featured-at-the-ois-retina-at-asrs-and-asrs-2021-annual-meeting/2480315/Ocuphire Pharma announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit (OIS) Retina@ASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX333
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-reports-additional-positive-data-from-its-phase-1-2-clinical-trial-in-patients-with-x-linked-retinitis-pigmentosa/2478525/Applied Genetic Technologies Corporation (AGTC) reported positive data from its ongoing phase 1/2 clinical program in patients with X-linked retinitis pigmentosa (XLRP). Visual sensitivity, visual acuity and safety data were reported for 12-month timepoints
- Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/tepezza-data-from-phase-2-clinical-trial-evaluate-longer-term-responses-in-people-living-with-thyroid-eye-disease-ted/2478415/Horizon Therapeutics announced new long-term follow-up data from the phase 2 clinical trial of Tepezza (teprotumumab-trbw), which showed a sustained response up to 1 year following completion of treatment for Thyroid Eye Disease (TED). These data will be presented as part of the
- Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/Aerie Pharmaceuticals announced successful interim 90-day topline data from its 6-month phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda to Ganfort, according to a company news release. Roclanda is marketed in the United States as Rocklatan (netarsudil and latanopro
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher